Subscribe To

Price Alert Latest News Economic Calendar News

RHHBY / Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological disorders will be presented at the 74th American Academy of Neurology (AAN) Annual Meeting being held 02-07 April in Seattle and virtually 24-26 April 2022. These data include twenty-four abstracts highlighting Roche's expansive neuroscience portfolio across five therapeutic areas, including OCREVUS® (ocrelizumab) in relapsing, secondary and primary progressive multiple sclerosis (RMS, SPMS and PPMS), EVRYDSI™ (risdiplam) in spinal muscular atrophy (SMA), ENSPRYNG™ (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD), along with data from investigational programs in Alzheimer's disease (AD) and Duchenne muscular dystrophy (DMD). Read More

Demo Live Account See Partner Details

Content Topics

Roche

Present

Data

Across

Broad

Impactful

Neuroscience

Portfolio

Annual

Meeting

Stock

RHHBY

Posted: Mar 25 2022, 02:00

Author Name: GlobeNewsWire

RHHBY News

By Barrons
October 23, 2023

Roche Agrees $7.1 Billion for Drug Company

It will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.

By Proactive Investors
October 23, 2023

Roche splashes US$7.1 billion on new irritable bowel drug

Roche has agreed to pay US$7.1 billion for an early-stage inflammatory bowel disease treatment developed by US rivals Roivant and Pfizer. For its mon

By CNBC
October 23, 2023

Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings

Swiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.

By Reuters
October 23, 2023

Roche buys Telavant Holdings for $7.1 billion

Roche on Monday said it will buy Telavant, a developer of a new treatment for inflamatory bowel diseases, for an initial $7.1 billion from American bi

By CNBC
October 22, 2023

India is a ‘slow trundling elephant' but a viable alternative to China, says veteran investor David Roche

Veteran Investor David Roche said India has been aligning itself with the "democratic alliances" of the "richest and most vibrant economies" in the wo

By Zacks Investment Research
October 19, 2023

Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale

Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuation

By Reuters
October 19, 2023

Roche's 9M sales down 6% on currency headwinds, drop in COVID sales

Roche said nine-month sales slipped 6% to 44.1 billion Swiss francs ($49.1 billion), hit by a sharp decline in sales of COVID-19 products and as a str

By Zacks Investment Research
October 16, 2023

Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study

Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relap

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.